Royalty Pharma Finance Trust New York City, NY - 10022

Royalty Pharma Finance Trust is categorized under Trust Services in New York City, NY and active since 2007.

Royalty Pharma Finance Trust was established in 2007, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Trust Services business, which does work in the BOTH market, and is classified as a Trust Services, under code number 523991 by the NAICS.

If you are seeking more information, feel free to contact Pablo Legorreta at the company’s single location by writing to 110 East 59th St Floor 33, New York City, New York NY 10022 or by phoning (212) 883-0200. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Royalty Pharma Finance Trust
Contact Person: Pablo Legorreta
Address: 110 East 59th St Floor 33, New York City, New York 10022
Phone Number: (212) 883-0200
Website Address: royaltypharma.com
Annual Revenue (USD): $100.000 to $499.999
Founded: 2007
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B & B2C
Business Category: Trust Services
SIC Code: 6733
NAICS Code: 523991
Share This Business:

Royalty Pharma Finance Trust was started in 2007 to provide professional Trust Services under the SIC code 6733 and NAICS code 523991. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact Pablo Legorreta for inquiries that concern Royalty Pharma Finance Trust by calling the company number (212) 883-0200, as your correspondence is most welcome. Additionally, the physical location of the single location of Royalty Pharma Finance Trust can be found at the coordinates 40.762683,-73.969621 as well as the street address 110 East 59th St Floor 33 in New York City, New York 10022.

For its online presence, you may visit Royalty Pharma Finance Trust’s website at royaltypharma.com and engage with its social media outlets through on Twitter and on Facebook.